{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castration-Resistant&page=17", "query": { "condition": "Castration-Resistant", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 666, "total_pages": 67, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castration-Resistant&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Castration-Resistant&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T18:46:02.452Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03093272", "title": "A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Leuprolide Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 9, "start_date": "2017-06-23", "completion_date": "2019-12-31", "has_results": true, "last_update_posted_date": "2020-04-09", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03093272" }, { "nct_id": "NCT03344211", "title": "Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Radium Ra 223 Dichloride", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2018-11-21", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03344211" }, { "nct_id": "NCT03834519", "title": "Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 793, "start_date": "2019-05-02", "completion_date": "2024-01-27", "has_results": true, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 29, "location_summary": "Fullerton, California • Los Angeles, California • Washington D.C., District of Columbia + 24 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Quincy", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03834519" }, { "nct_id": "NCT04927663", "title": "11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Solid Tumor, Adult", "Solid Tumor", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "11C-YJH08", "type": "DRUG" }, { "name": "Optional Tumor Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 2, "start_date": "2021-08-10", "completion_date": "2025-02-28", "has_results": true, "last_update_posted_date": "2025-05-20", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04927663" }, { "nct_id": "NCT05682443", "title": "ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "ONC-392 low", "type": "DRUG" }, { "name": "ONC-392 high", "type": "DRUG" }, { "name": "lutetium Lu 177 vipivotide tetraxetan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoC4, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 148, "start_date": "2023-12-11", "completion_date": "2027-11-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 23, "location_summary": "Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05682443" }, { "nct_id": "NCT01560923", "title": "Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "Indoximod", "type": "BIOLOGICAL" }, { "name": "Sipuleucel-T", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 47, "start_date": "2012-10-01", "completion_date": "2018-12-12", "has_results": true, "last_update_posted_date": "2020-04-03", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 4, "location_summary": "Chicago, Illinois • Minneapolis, Minnesota • New York, New York + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01560923" }, { "nct_id": "NCT02204072", "title": "BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "BI 836845", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2014-11-11", "completion_date": "2023-06-01", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 3, "location_summary": "Detroit, Michigan • New York, New York • Portland, Oregon", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02204072" }, { "nct_id": "NCT01549951", "title": "Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Orteronel+Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 50, "start_date": "2012-05", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-06-01", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01549951" }, { "nct_id": "NCT02655822", "title": "Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Cancer", "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Ciforadenant", "type": "DRUG" }, { "name": "Ciforadenant + atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 502, "start_date": "2016-01", "completion_date": "2021-07", "has_results": false, "last_update_posted_date": "2021-08-30", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 15, "location_summary": "Tucson, Arizona • San Francisco, California • Stanford, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02655822" }, { "nct_id": "NCT03042312", "title": "Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endocyte", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 71, "start_date": "2017-07-12", "completion_date": "2020-01-15", "has_results": true, "last_update_posted_date": "2021-03-24", "last_synced_at": "2026-10-29T18:46:02.452Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03042312" } ] }